56
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Can clinicians predict psychosis in an ultra high risk group?

&
Pages 625-630 | Received 18 Nov 2009, Accepted 07 Dec 2009, Published online: 16 Apr 2010

References

  • Yung AR, McGorry PD, McFarlane CA, Jackson HJ, Patton GC, Rakkar A. Monitoring and care of young people at incipient risk of psychosis. Schizophr Bull 1996; 22:283–303.
  • Yung AR, Phillips LJ, Yuen HP, . Psychosis prediction: 12-month follow up of a high-risk (“prodromal”) group. Schizophr Res 2003; 60:21–32.
  • Yung AR, Phillips LJ, Yuen HP, McGorry PD. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr Res 2004; 67:131–142.
  • Mason O, Startup M, Halpin S, Schall U, Conrad A, Carr V. Risk factors for transition to first episode psychosis among individuals with ‘at-risk mental states’. Schizophr Res 2004; 71:227–237.
  • Cannon TD, Cadenhead K, Cornblatt B, . Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry 2008; 65:28–37.
  • McGorry PD, Yung AR, Phillips LJ, . Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002; 59:921–928.
  • McGlashan TH, Zipursky RB, Perkins DO, . Olanzapine for treatment of the schizophrenia prodrome: 2 year results of a randomized placebo-controlled study. World J Biol Psychiatry 2004; 5:146.
  • Cornblatt BA, Lencz T, Smith CW, Correll CU, Auther AM, Nakayama E. The schizophrenia prodrome revisited: a neurodevelopmental perspective. Schizophr Bull 2003; 29:633–651.
  • McGorry PD, Yung AR, Bechdolf A, Amminger GP. Back to the future: predicting and reshaping the course of psychotic disorder. Arch Gen Psychiatry 2008; 65:25–27.
  • Center MM. PIER project overview, 2008; http://www.mmc.org/pier body.cfm?id=2104.
  • Corcoran C, Malaspina D, Hercher L. Prodromal interventions for schizophrenia vulnerability: The risks of being “at risk”. Schizophr Res 2005; 73:173–184.
  • McGorry PD, Nelson B, Amminger GP, . Intervention in the pre-psychotic period: A review and future directions. J Clin Psychiatry 2009; 70:1206–1212.
  • Dawes RM, Faust D, Meehl PE. Clinical versus actuarial judgment. Science 1989; 243:1668–1674.
  • Grove WM, Zald DH, Lebow BS, Snitz BE, Nelson C. Clinical versus mechanical prediction: a meta-analysis. Psychol Assess 2000; 12:19–30.
  • Meehl PE. Clinical versus statistical prediction. Minneapolis, MN: University of Minnesota Press; 1954.
  • McGorry PD, Yung AR, Phillips LJ. The “close-in” or ultra high-risk model: a safe and effective strategy for research and clinical intervention in prepsychotic mental disorder. Schizophr Bull 2003; 29:771–790.
  • Yung AR. Identification and treatment of the prodromal phase of psychotic disorders: perspectives from the PACE Clinic. Early Intervention in Psychiatry 2007; 1:224–235.
  • Yung AR, Yuen HP, McGorry PD, . Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Austr N Z J Psychiatry 2005; 39:964–971.
  • American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association; 1994.
  • First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders – Patient edition (SCID-I/P, Version 2.0). New York: Bimetrics Research Department; 1996.
  • Yung AR, Phillips LJ, McGorry PD. Treating schizophrenia in the prodromal phase. London: Taylor & Francis; 2004.
  • Yung AR, Yuen HP, Berger G, . Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk? Schizophr Bull 2007; 33:673–681.
  • McGlashan T, Zipursky R, Perkins D, . The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophr Res 2003; 61:7–18.
  • McGorry PD, Phillips LJ, Nelson B, . A double blind, placebo-controlled randomized trial of low-dose risperidone, cognitive-behaviour therapy, and befriending in young people with subthreshold symptoms at incipient risk of psychotic disorder: Six month outcome data. Schizophr Bull 2007; 33: 446.
  • Nelson B, Yung AR. Treatment of the schizophrenia prodrome, Mueser KT, Jeste DV. The clinical handbook of schizophrenia. New York: Guilford Press; 2007:698–715.
  • Yung AR. Commentary: The Schizophrenia Prodrome: A High-Risk Concept. Schizophr Bull 2003; 29:859–865.
  • Rümke C. The nuclear symptom of schizophrenia and the praecox feeling. History of Psychiatry 1941/1990; 1:331–341.
  • Grube M, Towards an empirically based validation of intuitive diagnostic: Rumke’s ‘praecox feeling’ across the schizophrenia spectrum: preliminary results. Psychopathology 2006; 39: 209–217.
  • Group IEPAW, International clinical practice guidelines for early psychosis. Br J Psychiatry 2005; 187:120–124.
  • Woods SW, Addington J, Cadenhead KS, . Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. Schizophr Bull 2009; 35:894–908.
  • Carpenter WT. Anticipating DSM-V: should psychosis risk become a diagnostic class? Schizophr Bull 2009; 35:841–843.
  • Regier DA. Time for a fresh start? Rethinking psychosis in DSM-V. Schizophr Bull 2007; 33:843–845.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.